John Patrick Sia, MD
Nephrology · Manchester, NHNPI 1255597464
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,940 of the $12,056 with a category attached, or 65.9%. 23 manufacturers reported payments, led by Boehringer Ingelheim at 45.8% of the total. Reporting peaked in 2024 at $7,642 and has fallen 62.8% since, to $2,840 in 2025. Among nephrology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $70.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- Lilly USA, LLC$3K
- AstraZeneca$844
- Amgen$477
- Bayer$369
- Otsuka America Pharmaceutical, Inc.$298
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$7,94066%
- Travel & lodging$1491%
- Food & beverage$3,87532%
- Education$911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $5,522 |
| Lilly USA, LLC | 10 | $2,882 |
| AstraZeneca | 27 | $844 |
| Amgen | 23 | $477 |
| Bayer | 19 | $369 |
| Otsuka America Pharmaceutical, Inc. | 11 | $298 |
| Mallinckrodt Hospital Products Inc. | 13 | $274 |
| Novartis | 10 | $204 |
| Ardelyx, Inc. | 4 | $196 |
| Akebia Therapeutics Inc | 7 | $136 |
| Fresenius USA Marketing, Inc. | 7 | $117 |
| Johnson & Johnson | 1 | $92 |
| Sanofi | 4 | $80 |
| AbbVie | 1 | $79 |
| Lexicon Pharmaceuticals, Inc. | 1 | $77 |
| GSK | 5 | $76 |
| ANI Pharmaceuticals, Inc. | 3 | $69 |
| Travere Therapeutics, Inc. | 5 | $63 |
| Vifor Pharma, Inc. | 3 | $54 |
| Apellis Pharmaceuticals, Inc. | 2 | $45 |
| Scpharmaceuticals Inc. | 2 | $40 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Calliditas Therapeutics US Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$7,940
- XPHOZAH 30 MG$146
- KRYSTEXXA$107
- Kerendia$103
How this compares
$12,056 in reported general payments places this provider in the 90th percentile of 33 nephrology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 14 | $270,535 |
| FarxigaDapagliflozin Propanediol | 73 | $78,986 |
| VelphoroSucroferric Oxyhydroxide | 41 | $74,263 |
| AuryxiaFerric Citrate | 19 | $42,436 |
| JardianceEmpagliflozin | 32 | $34,892 |
| XphozahTenapanor Hcl | 11 | $30,170 |
| Sevelamer Carbonate | 130 | $21,607 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,834 |
| Calcium Acetate | 33 | $2,638 |
| Potassium Chloride | 28 | $2,161 |
| Torsemide | 20 | $1,332 |
| Calcitriol | 43 | $1,060 |
| Midodrine Hcl | 12 | $728 |
| Losartan Potassium | 65 | $653 |
| Lisinopril | 72 | $552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $298 | $270,53514 claims |
| AstraZenecaFarxiga, Lokelma | $844 | $89,82089 claims |
| Fresenius USA Marketing, Inc.Velphoro | $117 | $74,26341 claims |
| Akebia Therapeutics IncAuryxia | $136 | $42,43619 claims |
| Boehringer IngelheimJardiance | $5,522 | $34,89232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 33 nephrology providers in New Hampshire.
Other nephrology in Manchester
- David FriedenbergManchester$25
- Kevin MeyerManchester$22
- Marilena CaldarusaManchester$19
- Peter CheungManchester$0
- Ana StankovicSalem$66K
- Elizabeth BrandtLebanon$41K
- Sucharit JoshiPortsmouth$6K
- Yishu HanConcord$1K
- Shaikh HoqueNashua$740
- Siddharth MehtaNashua$589
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.